Join to View Full Profile
3181 SW Sam Jackson Park RdPortland, OR 97239
Phone+1 503-494-7400
Fax+1 503-494-4749
Dr. Divanji is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Punag Divanji is chief of cardiology at SOC Telemed and and is an interventional
Cardiologist at OHSU in Portland, OR. He received his medical degree from University of Texas Southwestern Medical School and has been in practice 6 years. He specializes in interventional cardiology and is experienced in cardiology, clinical research, telemedicine, and healthcare management.
Education & Training
University of California (San Francisco)Fellowship, Cardiovascular Disease, 2015 - 2018
University of Texas Southwestern Medical CenterChief Residency, Internal Medicine, 2014 - 2015- University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2011 - 2014
University of Texas Southwestern Medical SchoolClass of 2011
Certifications & Licensure
WA State Medical License Current
CA State Medical License 2015 - 2025
OR State Medical License 2019 - 2025
TX State Medical License 2014 - 2025
AZ State Medical License 2022 - 2024
MO State Medical License 2021 - 2023
MS State Medical License 2021 - 2023- Join now to see all
Publications & Presentations
PubMed
- Clinicoeconomic burden among heart failure patients with severely reduced ejection fraction after hospital admission: HF-RESTORE.Heidi T May, Jeffrey L Anderson, Michael Butzner, Punag H Divanji, Joseph B Muhlestein
European Heart Journal. Quality of Care & Clinical Outcomes. 2025-03-03 - 1 citationsEffect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten.Donghong Xu, Justin D Lutz, Punag Divanji, Jianlin Li, Youcef Benattia
Clinical Pharmacokinetics. 2025-03-01 - 3 citationsPharmacokinetics, disposition, and biotransformation of the cardiac myosin inhibitor aficamten in humans.Donghong Xu, Punag Divanji, Adrienne Griffith, Rajaa Sukhun, Kathleen Cheplo
Pharmacology Research & Perspectives. 2024-10-01
Press Mentions
AHA: Postpartum Depression May Raise Heart RisksNovember 5th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
